Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone

BMC Cancer

Volumn 12, Issue , 2012, Pages

  van Oosterwijk, Jolieke G ^a   de Jong, Danielle ^a   van Ruler, Maayke A J H ^a   Hogendoorn, Pancras C W ^a   Dijkstra, P D Sander ^a   van Rijswijk, Carla S P ^a   Machado, Isidro ^b   Llombart Bosch, Antonio ^b   Szuhai, Karoly ^a   Bovée, Judith V M G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Bone neoplasm; Cell line; Chondrosarcoma; IDH1; IDH2; p16

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; PROTEIN P16; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARRAY COMPARATIVE GENOMIC HYBRIDIZATION; ARTICLE; CANCER GRADING; CARCINOGENICITY; CELL CULTURE; CELL STRAIN L2975; CELL STRAIN L3252; CELL STRAIN L835; CHONDROSARCOMA; CHROMOSOME ABERRATION; COBRA FLUORESCENCE IN SITU HYBRIDIZATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONVENTIONAL CENTRAL CHONDROSARCOMA; DEDIFFERENTIATED CHONDROSARCOMA; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KARYOTYPING; MALE; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE; ONCOGENE IDH; ONCOGENE TP53; SARCOMA CELL; TUMOR GROWTH; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CHONDROSARCOMA; COMPARATIVE GENOMIC HYBRIDIZATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MICE; MICE, NUDE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; RADIUS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84865322362     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-375     Document Type: Article

References (34)

1. Bertoni F, Bacchini P, Hogendoorn PCW. Chondrosarcoma. In World Health Organisation classification of tumours 2002, 247-251. Pathology and genetics of tumours of soft tissue and bone. Edited by: Fletcher CDM, Unni KK, Mertens F, Lyon: IARC Press.
2. Milchgrub S, Hogendoorn PCW, . In World Health Organisation classification of tumours Dedifferentiated chondrosarcoma 2002, 252-254. Pathology and genetics of tumours of soft tissue and bone. Edited by: Fletcher CDM, Unni KK, Mertens F, Lyon: IARC Press, In World Health Organisation classification of tumours.
3. Gelderblom H, Hogendoorn PCW, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AHM, Bovee JVMG. The clinical approach towards chondrosarcoma. Oncologist 2008, 13(3):320-329. 10.1634/theoncologist.2007-0237, 18378543.
4. Bovee JVMG, Hogendoorn PCW, Wunder JS, Alman BA. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer 2010, 10(7):481-488. 10.1038/nrc2869, 20535132.
5. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O'Donnell P, Grigoriadis A, Diss T, Eskandarpour M, Presneau N, Hogendoorn PCW, Futreal A, Tirabosco R, Flanagan AM. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 2011, 224(3):334-343. 10.1002/path.2913, 21598255.
6. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360(8):765-773. 10.1056/NEJMoa0808710, 2820383, 19228619.
7. Piaskowski S, Bienkowski M, Stoczynska-Fidelus E, Stawski R, Sieruta M, Szybka M, Papierz W, Wolanczyk M, Jaskolski DJ, Liberski PP, Rieske P. Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions. Br J Cancer 2011, 104(6):968-970. 10.1038/bjc.2011.27, 3065269, 21326241.
8. Calabuig-Farinas S, Benso RG, Szuhai K, Machado I, Lopez-Guerrero JA, De JD, Peydro A, Miguel TS, Navarro L, Pellin A, Llombart-Bosch A. Characterization of a new human cell line (CH-3573) derived from a grade II chondrosarcoma with matrix production. Pathol Oncol Res 2012, in press.
9. Kudo N, Ogose A, Hotta T, Kawashima H, Gu W, Umezu H, Toyama T, Endo N. Establishment of novel human dedifferentiated chondrosarcoma cell line with osteoblastic differentiation. Virchows Arch 2007, 451(3):691-699. 10.1007/s00428-007-0426-3, 17653762.
10. Yang L, Chen Q, Zhang S, Wang X, Li W, Wen J, Huang X, Zheng J, Huang G, Huang T, Ju G. A novel mutated cell line with characteristics of dedifferentiated chondrosarcoma. Int J Mol Med 2009, 24(4):427-435.
11. Tanke HJ, Wiegant J, Van Gijlswijk RPM, Bezrookove V, Pattenier H, Heetebrij RJ, Talman EG, Raap AK, Vrolijk J. New strategy for multi-colour fluorescence in situ hybrydisation: COBRA: COmbined Binary RAtio labelling. Eur J Hum Genet 1999, 7(1):2-11. 10.1038/sj.ejhg.5200265, 10094185.
12. Cleton-Jansen AM, van Beerendonk HM, Baelde HJ, Bovée JVMG, Karperien M, Hogendoorn PCW. Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Clin Cancer Res 2005, 11(22):8028-8035. 10.1158/1078-0432.CCR-05-1253, 16299232.
13. Atienzar FA, Tilmant K, Gerets HH, Toussaint G, Speeckaert S, Hanon E, Depelchin O, Dhalluin S. The Use of Real-Time Cell Analyzer Technology in Drug Discovery: Defining Optimal Cell Culture Conditions and Assay Reproducibility with Different Adherent Cellular Models. J Biomol Screen 2011, 16(6):575-587. 10.1177/1087057111402825, 21518825.
14. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de AE, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PCW, Buerger H, Aigner T, Gabbert HE. Poremba C. Molecular characterization of commonly used cell lines for bone tumor research a trans-European EuroBoNet effort. Genes Chromosomes Cancer 2010, 49(1):40-51. 10.1002/gcc.20717, 19787792.
15. Pansuriya TC, van Eijk R, d'Adamo P, van Ruler MA, Kuijjer ML, Oosting J, Cleton-Jansen AM, van Oosterwijk JG, Verbeke SL, Meijer D, van WT, Nord KH, Sangiorgi L, Toker B, Liegl-Atzwanger B, San-Julian M, Sciot R, Limaye N, Kindblom LG, Daugaard S, Godfraind C, Boon LM, Vikkula M, Kurek KC, Szuhai K, French PJ, Bovée JVMG. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 2011, 43(12):1256-1261. 10.1038/ng.1004, 3427908, 22057234.
16. van Eijk R, Licht J, Schrumpf M, Talebian YM, Ruano D, Forte GI, Nederlof PM, Veselic M, Rabe KF, Annema JT, Smit V, Morreau H, van Wezel T. Rapid KRAS: EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS ONE 2011, 6(3):e17791. 10.1371/journal.pone.0017791, 3050927, 21408138.
17. De Jong D, Verbeke SL, Meijer D, Hogendoorn PCW, Bovee JVMG, Szuhai K. Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples. BMC Res Notes 2011, 4:1. 10.1186/1756-0500-4-1, 3024235, 21205301.
18. Schrage YM, Lam S, Jochemsen AG, Cleton-Jansen AM, Taminiau AHM, Hogendoorn PCW, Bovee JVMG. Central chondrosarcoma progression is associated with pRb pathway alterations; CDK4 downregulation and p16 overexpression inhibit cell growth in vitro. J Cell Mol Med 2008, 13(9):2843-2852.
19. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone. A clinicopathologic analysis with emphasis on histologic grading. Cancer 1977, 40:818-831. 10.1002/1097-0142(197708)40:2<818::AID-CNCR2820400234>3.0.CO;2-B, 890662.
20. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009, 174(4):1149-1153. 10.2353/ajpath.2009.080958, 2671348, 19246647.
21. Luchman HA, Stechishin OD, Dang NH, Blough MD, Chesnelong C, Kelly JJ, Nguyen SA, Chan JA, Weljie AM, Cairncross JG, Weiss S. An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro Oncol 2012, 14(2):184-191. 10.1093/neuonc/nor207, 22166263.
22. Asp J, Sangiorgi L, Inerot SE, Lindahl A, Molendini L, Benassi MS, Picci P. Changes of the p16 gene but not the p53 gene in human chondrosarcoma tissues. Int J Cancer 2000, 85(6):782-786. 10.1002/(SICI)1097-0215(20000315)85:6<782::AID-IJC7>3.0.CO;2-O, 10709095.
23. Asp J, Brantsing C, Lovstedt K, Benassi MS, Inerot S, Gamberi G, Picci P, Lindahl A. Evaluation of p16 and Id1 status and endogenous reference genes in human chondrosarcoma by real-time PCR. Int J Oncol 2005, 27(6):1577-1582.
24. Ropke M, Boltze C, Neumann HW, Roessner A, Schneider-Stock R. Genetic and epigenetic alterations in tumor progression in a dedifferentiated chondrosarcoma. Pathol Res Pract 2003, 199(6):437-444. 10.1078/0344-0338-00443, 12924447.
25. van Beerendonk HM, Rozeman LB, Taminiau AHM, Sciot R, Bovée JVMG, Cleton-Jansen AM, Hogendoorn PCW. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression. J Pathol 2004, 202(3):359-366. 10.1002/path.1517, 14991902.
26. Meijer D, de Jong D, Pansuriya TC, van den Akker BE, Picci P, Szuhai K, Bovee JVMG. Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. Genes Chromosomes Cancer 2012, 51(10):899-909. 10.1002/gcc.21974, 22674453.
27. Fahham N, Sardari S, Ostad SN, Vaziri B, Ghahremani MH. C-terminal domain of p16(INK4a) is adequate in inducing cell cycle arrest, growth inhibition and CDK4/6 interaction similar to the full length protein in HT-1080 fibrosarcoma cells. J Cell Biochem 2010, 111(6):1598-1606. 10.1002/jcb.22892, 21053367.
28. Li WW, Takahashi N, Jhanwar S, Cordon-Cardo C, Elisseyeff Y, Jimeno J, Faircloth G, Bertino JR. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 2001, 7(9):2908-2911.
29. Rasheed S, Nelson-Rees WA, Toth EM, Arnstein P, Gardner MB. Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer 1974, 33(4):1027-1033. 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z, 4132053.
30. Scully SP, Berend KR, Toth A, Qi WN, Qi Z, Block JA. Marshall Urist Award. Interstitial collagenase gene expression correlates with in vitro invasion in human chondrosarcoma. Clin Orthop Relat Res 2000, 376:291-303.
31. Gil-Benso R, Lopez-Gines C, Lopez-Guerrero JA, Carda C, Callaghan RC, Navarro S, Ferrer J, Pellin A, Llombart-Bosch A. Establishment and characterization of a continuous human chondrosarcoma cell line, ch-2879: comparative histologic and genetic studies with its tumor of origin. Lab Invest 2003, 83(6):877-887.
32. Kunisada T, Miyazaki M, Mihara K, Gao C, Kawai A, Inoue H, Namba M. A new human chondrosarcoma cell line (OUMS-27) that maintains chondrocytic differentiation. Int J Cancer 1998, 77(6):854-859. 10.1002/(SICI)1097-0215(19980911)77:6<854::AID-IJC10>3.0.CO;2-1, 9714054.
33. Van Oosterwijk JG, Herpers B, Meijer D, Briaire-de Bruijn IH, Cleton-Jansen AM, Gelderblom H, van de Water B, Bovee JVMG. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance. Ann Oncol 2012, 23:1617-1626. 10.1093/annonc/mdr512, 22112972.
34. Bovée JVMG, Cleton-Jansen AM, Rosenberg C, Taminiau AHM, Cornelisse CJ, Hogendoorn PCW. Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis. J Pathol 1999, 189:454-462. 10.1002/(SICI)1096-9896(199912)189:4<454::AID-PATH467>3.0.CO;2-N, 10629543.